We evaluated modifications in the hemostatic balance of different concentrations of
apixaban (APIX) in 25 healthy donors and 53 patients treated with aspirin (ASA, n= 21), ASA …

Introduction Mechanisms of action of direct oral anticoagulants (DOAC) suggest a potential
therapeutic use in the prevention of thrombotic complications in arterial territories. However …

INTRODUCTION Apixaban is a novel oral anticoagulant (NOAC) that specifically inhibits
factor Xa (FXa). It is approved in several countries for the prevention of venous …

Apixaban does not require monitoring nor frequent dose adjustment. However, searching for
the optimal dose for the individual patient may be useful in some situations. Moreover, there …

Background Four‐factor prothrombin complex concentrate (PCC)(Cofact; Sanquin Blood
Supply) 50 IU kg− 1 increased thrombin generation beyond baseline values in healthy …

Apixaban is a new oral anticoagulant with a specific inhibitory action on FXa. No information
is available on the reversal of the antihemostatic action of apixaban in experimental or …

Essentials• Prothrombin complex concentrates (PCCs) may reverse the effect of factor Xa
(FXa) inhibitors.• We conducted an open‐label, randomized, placebo‐controlled, three …

抄録< jats: title> Summary</jats: title>< jats: p> While laboratory monitoring is not required in
patients treated with apixaban, a direct factor-Xa inhibitor, assessment of its concentration is …

Background: There is a need to optimize pharmacological treatment in patients with acute
coronary syndrome and concomitant atrial fibrillation, in particular with newer antithrombotic …

Background: Apixaban is a newly developed direct oral anticoagulant targeting activated
factor X (FXa). The degree of interference of apixaban with coagulation parameters has not …